Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report

BACKGROUND: Cabazitaxel (CBZ) chemotherapy for metastatic castration-resistant prostate cancer (mCRPC) is believed to be palliative because the radiological response rate is low and a durable response is rare. Here, we describe a rare case of a patient with mCRPC who was treated with CBZ chemotherap...

Descripción completa

Detalles Bibliográficos
Autores principales: Kosaka, Takeo, Hongo, Hiroshi, Oya, Mototsugu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558884/
https://www.ncbi.nlm.nih.gov/pubmed/31185946
http://dx.doi.org/10.1186/s12885-019-5782-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558884/
https://www.ncbi.nlm.nih.gov/pubmed/31185946
http://dx.doi.org/10.1186/s12885-019-5782-2

Ejemplares similares